Chronic Lymphocytic Leukemia Up Regulated 1 Opposite Strand Protein (CLLU1OS)

[Edit]

Putative chronic lymphocytic leukemia up-regulated protein 1 opposite strand transcript protein

Chronic Lymphocytic Leukemia Up Regulated 1 Opposite Strand Protein (CLLU1OS)
CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. High levels of CLLU1 expression were associated with shorter overall survival, with a 7% increase in risk of early death by each doubling of the CLLU1 expression level. Stratification for age at diagnosis demonstrated a strong prognostic significance of CLLU1 expression in patients younger than 70 years, but not in patients aged 70 or older.
CLLU1 expression analysis added further prognostic information within all prognostic subgroups, with the exception of patients with unmutated IgV(H) CLL. Only CLLU1 expression and IgV(H) mutational status had independent predictive power. Thus, analysis of CLLU1 expression is highly applicable in risk prediction in CLL for patients of an age eligible for risk stratification.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Chronic Lymphocytic Leukemia Up Regulated 1 Opposite Strand Protein (CLLU1OS) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Chronic Lymphocytic Leukemia Up Regulated 1 Opposite Strand Protein (CLLU1OS) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Chronic Lymphocytic Leukemia Up Regulated 1 Opposite Strand Protein (CLLU1OS) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Chronic Lymphocytic Leukemia Up Regulated 1 Opposite Strand Protein (CLLU1OS) CLIA Kit Customized Service Offer
n/a ELISA Kit for Chronic Lymphocytic Leukemia Up Regulated 1 Opposite Strand Protein (CLLU1OS) ELISA Kit Customized Service Offer
  1. "Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia."Blood 107:2904-2911(2006) [PubMed] [Europe PMC] [Abstract]